|
🐜
|
Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
14 auth.
L. Emmett,
P. V. van Leeuwen,
Rohan Nandurkar,
M. Scheltema,
T. Cusick,
G. Hruby,
A. Kneebone,
T. Eade,
G. Fogarty,
R. Jagavkar,
...
Quoc Nguyen,
B. Ho,
A. Joshua,
P. Stricker
|
7 |
2017 |
7
🐜
|
|
🐜
|
3-Year Freedom from Progression After 68Ga-PSMA PET/CT–Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
21 auth.
L. Emmett,
Reuben Tang,
Rohan Nandurkar,
G. Hruby,
P. Roach,
J. Watts,
T. Cusick,
A. Kneebone,
B. Ho,
L. Chan,
...
P. V. van Leeuwen,
M. Scheltema,
Andrew Nguyen,
Charlotte Yin,
A. Scott,
Colin I. Tang,
M. McCarthy,
K. Fullard,
M. Roberts,
R. Francis,
P. Stricker
|
6 |
2019 |
6
🐜
|
|
🐜
|
Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer
12 auth.
P. V. van Leeuwen,
M. Donswijk,
Rohan Nandurkar,
P. Stricker,
B. Ho,
S. Heijmink,
...
E. Wit,
C. Tillier,
Erik van Muilenkom,
Quoc Nguyen,
H. G. van der Poel,
L. Emmett
|
6 |
2019 |
6
🐜
|
|
🦁
|
68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
12 auth.
Rohan Nandurkar,
P. V. van Leeuwen,
P. Stricker,
H. Woo,
Rajdeep K Kooner,
C. Yuen,
...
G. O'Neill,
D. Ende,
T. Cusick,
B. Ho,
Adam Hickey,
L. Emmett
|
4 |
2019 |
4
🦁
|
|
🐜
|
The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study
26 auth.
F. Zattoni,
G. Marra,
V. Kasivisvanathan,
J. Grummet,
Rohan Nandurkar,
G. Ploussard,
J. Olivier,
P. Chiu,
M. Valerio,
P. Gontero,
Hongqian Guo,
J. Zhuang,
F. Barletta,
R. Leni,
M. Frydenberg,
...
D. Moon,
U. Hanegbi,
Adam Landaumailto,
R. Snow,
M. Apfelbeck,
A. Kretschmer,
R. V. D. van den Bergh,
G. Novara,
A. Briganti,
F. Dal Moro,
G. Gandaglia
|
4 |
2022 |
4
🐜
|
|
🐜
|
Event-free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups.
16 auth.
M. Roberts,
M. Chatfield,
G. Hruby,
Rohan Nandurkar,
P. Roach,
J. Watts,
T. Cusick,
A. Kneebone,
T. Eade,
B. Ho,
...
Andrew Nguyen,
Colin I. Tang,
M. McCarthy,
R. Francis,
P. Stricker,
L. Emmett
|
3 |
2022 |
3
🐜
|
|
🐜
|
Distribution of prostate cancer recurrences on gallium‐68 prostate‐specific membrane antigen (68Ga‐PSMA) positron‐emission/computed tomography after radical prostatectomy with pathological node‐positive extended lymph node dissection
12 auth.
Thijs H. Huits,
H. Luiting,
H. G. van der Poel,
Rohan Nandurkar,
M. Donswijk,
E. Schaake,
...
W. Vogel,
M. Roobol,
E. Wit,
P. Stricker,
L. Emmett,
P. V. van Leeuwen
|
3 |
2020 |
3
🐜
|
|
🐜
|
Event‐free survival after radical prostatectomy according to prostate‐specific membrane antigen‐positron emission tomography and European Association of Urology biochemical recurrence risk groups
16 auth.
M. Roberts,
Mark D. Chatfield,
G. Hruby,
Rohan Nandurkar,
P. Roach,
J. Watts,
T. Cusick,
A. Kneebone,
T. Eade,
B. Ho,
...
Andrew Nguyen,
Colin I. Tang,
M. McCarthy,
R. Francis,
P. Stricker,
L. Emmett
|
3 |
2022 |
3
🐜
|
